Introduction Ankylosing spondylitis (AS) is a chronic inflammatory condition of the axial skeleton, treated initially with NSAIDs (1). For patients with active disease despite conventional therapy, biologics like TNF-α or IL-17A inhibitors are recommended (1). Secukinumab, a first-in-class IL-17A inhibitor, is approved for AS, plaque psoriasis, and